After a weak clinical trial result that wiped more than half of Prima BioMed ’s value, chief executive Matthew Lehman is pinning his hopes on a smaller group of patients who responded positively to the company’s ovarian cancer therapy.

At least one analyst has described the revised strategy as risky, but Mr Lehman is upbeat.